The CRR of neoadjuvant anti‐PD‐1/PD‐L1 therapy in lung cancer was 0.200 (95% CI 0.117, 0.282, I2 = 37%), and the MRR was 0.471 (95% CI 0.367, 0.575, I2 = 0%). Here, PDCD1 is linked to lung carcinoma.